Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.64 USD | -0.47% | -9.16% | -13.00% |
Apr. 29 | J&J, Bristol Myers lose challenges to US drug price negotiation program | RE |
Apr. 29 | Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.00% | 90.92B | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol-Myers' Reblozyl Approved in EU as First-Line Treatment of Transfusion-Dependent Anemia